VIGL vs. CMPS, GOSS, ESPR, PROK, CRVS, TKNO, ANNX, MBX, CADL, and AQST
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include COMPASS Pathways (CMPS), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), ProKidney (PROK), Corvus Pharmaceuticals (CRVS), Alpha Teknova (TKNO), Annexon (ANNX), MBX Biosciences (MBX), Candel Therapeutics (CADL), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Vigil Neuroscience vs.
Vigil Neuroscience (NASDAQ:VIGL) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
COMPASS Pathways' return on equity of -63.85% beat Vigil Neuroscience's return on equity.
Vigil Neuroscience presently has a consensus price target of $16.25, indicating a potential upside of 828.57%. COMPASS Pathways has a consensus price target of $21.83, indicating a potential upside of 611.18%. Given Vigil Neuroscience's higher possible upside, equities research analysts plainly believe Vigil Neuroscience is more favorable than COMPASS Pathways.
COMPASS Pathways received 32 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 84.62% of users gave Vigil Neuroscience an outperform vote while only 81.25% of users gave COMPASS Pathways an outperform vote.
Vigil Neuroscience has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500.
COMPASS Pathways is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vigil Neuroscience had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Vigil Neuroscience and 1 mentions for COMPASS Pathways. Vigil Neuroscience's average media sentiment score of 0.67 beat COMPASS Pathways' score of 0.00 indicating that Vigil Neuroscience is being referred to more favorably in the media.
83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 33.0% of Vigil Neuroscience shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Vigil Neuroscience beats COMPASS Pathways on 9 of the 14 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
This page (NASDAQ:VIGL) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy VIGL Stock Free VIGL Stock Alerts